Cited by 64

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

HPV16-E6 associated hTERT promoter acetylation is E6AP dependent, increased in later passage cells and enhanced by loss of p300

James, Michael A., Lee, John H., Klingelhutz, Aloysius J.·2006·International Journal of Cancer

Abstract

The E6 oncoprotein from high‐risk HPV types activates human telomerase reverse transcriptase (hTERT) transcription in human keratinocytes. Studies on how E6 regulates hTERT have implicated E‐box or X‐box elements in the hTERT promoter (Veldman et al., Proc Natl Acad Sci USA 2003;100:8211–14; Oh et al., J Virol 2001;75:5559–66; Gewin et al., Genes Dev 2004;18:2269–82), but the mechanism of activation by E6 is still controversial and not well defined. Here, we demonstrate that induction of both hTERT expression and telomerase activity by HPV‐16 E6 in early passage keratinocytes is associated with acetylation of histone H3 at the hTERT promoter, is dependent on the E6 associated protein (E6AP) and is not exclusively reliant on E‐box or X‐box elements. Further increases in histone acetylation of the hTERT promoter and hTERT transcriptional activity in E6 expressing cells that had been passaged extensively in culture were found to occur only with the endogenous promoter and not with an exogenously introduced hTERT promoter construct. Telomerase activity at both early and late passages, however, was dependent on E6AP expression, implying a continued reliance on E6 function for telomerase activity. Our results demonstrate that E6 induces hTERT promoter acetylation, but that further increases in telomerase activity and histone acetylation in later passage E6 expressing cells are independent of E6 activation of the core hTERT promoter. We also provide evidence that the transcription factor p300 is a potential repressor of telomerase activation and histone acetylation in the context of E6 expression. These studies give insight into how immortalization by HPV results in upregulation of hTERT and furthers our understanding of how telomerase is activated during the process of malignant transformation. © 2006 Wiley‐Liss, Inc.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ijc.22064

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 29

  1. 10.1006/viro.1997.8851 · DOI · Paper page
  2. 10.1006/viro.1997.8860 · DOI
  3. 10.1038/380079a0 · DOI · Paper page
  4. 10.1016/S0002-9440(10)62552-7 · DOI · Paper page
  5. 10.1128/JVI.75.15.7198-7201.2001 · DOI · Paper page
  6. 10.1074/jbc.M410343200 · DOI · Paper page
  7. 10.1128/JVI.77.12.6957-6964.2003 · DOI
  8. Ulaner GA, 1998, Telomerase activity in human development is regulated by human telomerase reverse transcriptase (hTERT) transcription and by alternate splicing of hTERT transcripts, Cancer Res, 58, 4168
  9. Crowe DL, 2005, Mechanism of telomerase repression during terminal differentiation of normal epithelial cells and squamous carcinoma lines, Int J Oncol, 27, 847
  10. 10.1006/excr.2001.5462 · DOI
  11. 10.1093/nar/29.14.3006 · DOI
  12. 10.1093/intimm/dxh201 · DOI
  13. 10.1128/JVI.75.9.4467-4472.2001 · DOI · Paper page
  14. 10.1128/JVI.75.12.5559-5566.2001 · DOI · Paper page
  15. 10.1073/pnas.1435900100 · DOI · Paper page
  16. 10.1006/viro.2002.1542 · DOI
  17. 10.1128/jvi.68.9.5698-5705.1994 · DOI · Paper page
  18. 10.1128/JVI.73.8.6209-6219.1999 · DOI · Paper page
  19. 10.1073/pnas.0401801101 · DOI
  20. 10.1074/jbc.M206064200 · DOI
  21. 10.1002/ijc.10921 · DOI
  22. 10.1002/ijc.10082 · DOI
  23. 10.1074/jbc.C000637200 · DOI
  24. 10.1016/j.ejcb.2004.12.010 · DOI
  25. 10.1038/25166 · DOI · Paper page
  26. 10.1074/jbc.M408633200 · DOI
  27. 10.1073/pnas.081141998 · DOI
  28. 10.1038/sj.onc.1203562 · DOI
  29. 10.1128/JVI.77.18.9852-9861.2003 · DOI · Paper page

Cited by

See all 64

Metadata

Authors
James, M. A., Lee, J. H., & Klingelhutz, A. J.
Venue
International Journal of Cancer
Publisher
Wiley
Published
2006-05-17
Volume
119
Issue
8
Pages
1878-1885
ISSN
  • 0020-7136
  • 1097-0215
Cited by
64
References
4
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review